flavin-mononucleotide and MELAS-Syndrome

The therapeutic efficacy of a regimen consisting of intravenous injection of Cardiocrome, containing cytochrome c, flavin mononucleotide and thiamine diphosphate for mitochondrial encephalomyopathy (MEM) was examined. This combined therapy was applied to nine patients with MEM, including four with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. For the standard regimen, Cardiocrome was first injected daily, usually for 4 weeks, and later by means of intermittent injections for maintenance treatment. Clinical improvement was obtained in eight of the patients. Improvement was observed in the muscle symptoms of easy fatigability, motor disability and severity of stroke-like episodes, as well as in various other symptoms such as phosphate, tinnitus, headache, corneal edema, chilblains, thalamic pain, respiratory failure, and nystagmus. This clinical improvement was maintained for more than 1 year by additional intermittent injections. In conclusion, this therapy was fairly effective for the management of patients with MEM.

Topics: Adolescent; Adult; Cerebrospinal Fluid Proteins; Child; Child, Preschool; Cytochrome c Group; Cytochrome-c Oxidase Deficiency; Cytochromes c; Drug Combinations; Female; Flavin Mononucleotide; Humans; Kearns-Sayre Syndrome; Lactates; Male; MELAS Syndrome; MERRF Syndrome; Mitochondrial Encephalomyopathies; Riboflavin; Thiamine; Thiamine Pyrophosphate